Details of the Drug Metabolized by Drug-Metabolizing Enzyme (DME)

General Information of Drug (ID: DR5321)
Drug Name
Lenvatinib
Synonyms E 7080; E-7080, E7080; 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide
Indication Thyroid cancer [ICD11: 2D10] Approved [1]
Hepatocellular carcinoma [ICD11: ICD11: 2C12] Phase 3 [2]
Renal cell carcinoma [ICD11: ICD11: 2C90] Phase 3 [3]
Melanoma [ICD11: ICD11: 2C30] Phase 2 [4]
Solid tumour/cancer [ICD11: ICD11: 2A00-2F9Z] Phase 1/2 [5]
Ovarian cancer [ICD11: ICD11: 2C73] Phase 1 [6]
Lung cancer [ICD11: ICD11: 2C25] Application submitted [7]
Structure
3D MOL 2D MOL
Pharmaceutical Properties Molecular Weight 426.9 Topological Polar Surface Area 116
Heavy Atom Count 30 Rotatable Bond Count 6
Hydrogen Bond Donor Count 3 Hydrogen Bond Acceptor Count 5
Cross-matching ID
PubChem CID
9823820
ChEBI ID
CHEBI:85994
CAS Number
417716-92-8
TTD Drug ID
D0R0FO
Formula
C21H19ClN4O4
Canonical SMILES
COC1=CC2=NC=CC(=C2C=C1C(=O)N)OC3=CC(=C(C=C3)NC(=O)NC4CC4)Cl
InChI
InChI=1S/C21H19ClN4O4/c1-29-19-10-17-13(9-14(19)20(23)27)18(6-7-24-17)30-12-4-5-16(15(22)8-12)26-21(28)25-11-2-3-11/h4-11H,2-3H2,1H3,(H2,23,27)(H2,25,26,28)
InChIKey
WOSKHXYHFSIKNG-UHFFFAOYSA-N
The Metabolic Roadmap of This Drug
The Full List of Drug Metabolites (DM) of This Drug
DM Name DM ID PubChem ID Reaction DM Level REF
Lenvatinib N-oxide DM000236
101562919
Unclear - Unclear 1 [8]
N-descyclopropyl lenvatinib DM000235
22936448
Unclear - Unclear 1 [8]
O-demethyl Lenvatinib DM000230
135566046
Unclear - Unclear 1 [8]
The Full List of Metabolic Reaction (MR) of This Drug
MR ID Reactant Product MR Type DME REF
MR010932 Lenvatinib Lenvatinib N-oxide Unclear - Unclear CYP3A4 [8]
MR010933 Lenvatinib O-demethyl Lenvatinib Unclear - Unclear CYP1A1 ... [8]
MR010934 Lenvatinib N-descyclopropyl lenvatinib Unclear - Unclear CYP2B6 ... [8]
Drug-Metabolizing Enzyme(s) (DME) Metabolizing This Drug
DME Name DME Info Species Uniprot ID EC Number REF
Cytochrome P450 1A1 (CYP1A1) DME0006 Homo sapiens
CP1A1_HUMAN
1.14.14.1
[8]
Cytochrome P450 1A2 (CYP1A2) DME0003 Homo sapiens
CP1A2_HUMAN
1.14.14.1
[8]
Cytochrome P450 2A6 (CYP2A6) DME0005 Homo sapiens
CP2A6_HUMAN
1.14.14.1
[8]
Cytochrome P450 2B6 (CYP2B6) DME0020 Homo sapiens
CP2B6_HUMAN
1.14.14.1
[8]
Cytochrome P450 3A4 (CYP3A4) DME0001 Homo sapiens
CP3A4_HUMAN
1.14.14.55
[9]
Cytochrome P450 3A5 (CYP3A5) DME0012 Homo sapiens
CP3A5_HUMAN
1.14.14.1
[8]
Mephenytoin 4-hydroxylase (CYP2C19) DME0021 Homo sapiens
CP2CJ_HUMAN
1.14.14.1
[8]
⏷ Show the Full List of 7  DME(s)
References
1 FDA Approved Drug Products from FDA Official Website. 2018. Application Number: (ANDA) 208627.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 Emerging drugs for ovarian cancer. Expert Opin Emerg Drugs. 2008 Sep;13(3):523-36.
7 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8 The impact of individual human cytochrome P450 enzymes on oxidative metabolism of anticancer drug lenvatinib
9 Clinical Pharmacokinetic and Pharmacodynamic Profile of Lenvatinib, an Orally Active, Small-Molecule, Multitargeted Tyrosine Kinase Inhibitor

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.